Abbott's binaxnow™ rapid antigen self test receives fda emergency use authorization for asymptomatic, over-the-counter, non-prescription, multi-test use

Abbott park, ill., march 31, 2021 /prnewswire/ -- abbott (nyse: abt) announced today it has received u.s. food and drug administration (fda) emergency use authorization (eua) for over-the-counter, non-prescription, asymptomatic use of its binaxnow™ covid-19 ag self test for detection of covid-19 infection.
ABT Ratings Summary
ABT Quant Ranking